News >

Predictive Biomarkers Needed for Immunotherapy Combo Choice in Frontline RCC

Jessica Hergert
Published: Thursday, Jan 02, 2020

Ulka Vaishampayan, MD, a professor of oncology at Wayne State University, and chief of the Solid Tumor Program at Barbara Ann Karmanos Cancer Institute

Ulka Vaishampayan, MD

In just over 1 year, 3 immunotherapy combinations were approved for the frontline treatment of patients with metastatic renal cell carcinoma (mRCC). These advancements, however, have highlighted a need to identify biomarkers that can guide treatment selection for these patients, said Ulka Vaishampayan, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication